Liposomes in drug delivery: A patent review (2007 - present)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 11, 2013, Pages 1399-1414

  Arias, José L ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Active targeting; Drug delivery; Enhanced permeation and retention effect; Ligand receptor targeting; Liposome; Nanotoxicity; Passive targeting; Stimuli sensitive nanomaterial; Theranosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAMPTOTHECIN; CARBONIC ACID; CISPLATIN; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRUG CARRIER; FLOXURIDINE; FLUOROURACIL; GLYCEROL; INOSITOL; LATANOPROST; LIGAND; LIPOPLATIN; LIPOSOME; METHOTREXATE; NANOMATERIAL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHORIC ACID; PHOTOSENSITIZING AGENT; SIALIC ACID; SULFURIC ACID; UNCLASSIFIED DRUG; VACCINE; VINBLASTINE;

ATHEROSCLEROSIS; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL ADHESION; DISEASE SEVERITY; DISEASES; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; GENE TARGETING; HUMAN; IMMUNOGENICITY; LIPID VESICLE; LIPOSOMAL DELIVERY; MEDICINE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PATENT; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PUBLICATION; REVIEW; RISK; SUSTAINED DRUG RELEASE; SYNTHESIS;

ANIMALS; CELL ADHESION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPOSOMES; NANOPARTICLES; PATENTS AS TOPIC;

EID: 84886895750     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.828035     Document Type: Review

References (104)

1. Arias JL. Drug targeting strategies in cancer treatment: An overview. Mini Rev Med Chem 2011;11:1-17
2. Lammers T, Subr V, Peschke P. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 2008;99:900-10
3. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20
4. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed 2008;3:21-9
5. Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface 2010;7:S55-66
6. Yang J, Park SB, Yoon HG, et al. Preparation of poly "-caprolactone nanoparticles containing magnetite for magnetic drug carrier. Int J Pharm 2006;324:185-90
7. Esmaeilia F, Dinarvand R, Ghahremani MH, et al. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anticancer Drugs 2010;21:43-52
8. Fischer HC, Chan WCW. Nanotoxicity: The growing need for in vivo study. Curr Opin Biotechnol 2007;18:565-71
9. Dandamudi S, Campbell RB. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 2007;1768:427-38
10. Schroeder A, Sigal A, Turjeman K, Barenholz Y. Using PEGylated nano-liposomes to target tissue invaded by a foreign body. J Drug Target 2008;16:591-5
11. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm 2009;366:201-10
12. Langereis S, Keupp J, van Velthoven JL, et al. A temperature-sensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery. J Am Chem Soc 2009;131:1380-1
13. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: Design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev 2012;112:5818-78
14. Harashima H, Hiraiwa T, Ochi Y, Kiwada H. Size dependent liposome degradation in blood: In vivo/in vitro correlation by kinetic modeling. J Drug Target 1995;3:253-61
15. Clares B, Medina MM, Gallardo V, Ruíz MA. Multilamellar liposomes of triamcinolone acetonide: Preparation, stability and characterization. J Liposome Res 2009;19:197-206
16. Arias JL, Clares B, Morales ME, et al. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets 2011;12:1151-65
17. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999;19:317-57
18. Zanin MHA, Torriani ICL, Zollner RL, Santana MHA. Physical characterization of surface-modified liposomes by incorporation of gangliosides designed for immunotherapies. Colloids Surf A Physicochem Eng Asp 2004;251:175-82
19. Opanasopit P, Sakai M, Nishikawa M, et al. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release 2002;80:283-94
20. Hermes Bioscience, Inc. Liposomes useful for drug delivery. EP1746976; 2007
21. The Regents of the University of California. Zhang L, Pornpattananangkul D, Huang CME. Triggered cargo release from nanoparticle stabilized liposomes. WO2011112883; 2011
22. Statens Seruminstitut. Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids. EP1765289; 2007
23. Bin D, Ying L, Xiaotian L, et al. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm 2010;384:140-7
24. Elmi MM, Sarbolouki MN. A simple method for preparation of immuno-magnetic liposomes. Int J Pharm 2001;215:45-50
25. Alza Corp. Zhang Y, Luo B, Iyer L. Liposomal delivery vehicle for hydrophobic drugs. WO2007005754; 2007
26. Pinkhassik E, Danila DC. Aminophosphonate carriers for liposome-based drug release systems. WO2009114538; 2009
27. Schmidt MA, Miller JJ. Therapeutic liposomes and methods for producing and using the same. WO2011143271; 2011
28. Polymun Scient Immunbio Forsch. Superloaded liposomes for drug delivery. EP1748760; 2007
29. Kulkarni SB, Vargha-Butler EI. Study of liposomal drug delivery systems 2. Encapsulation efficiencies of some steroids in MLV liposomes. Colloids Surf B Biointerfaces 1995;4:77-85
30. Novosom AG. Serum stable liposomes comprising amphoter II lipid mixtures. EP1764089; 2007
31. Wisconsin Alumni Research Foundation. Xiong MP, Wang Y, Tu S. Liposome-encapsulated hydrogels for use in a drug delivery system. WO2012155048; 2012
32. Lee S, Lee J, Choi YW. Skin permeation enhancement of ascorbyl palmitate by liposomal hydrogel (lipogel) formulation and electrical assistance. Biol Pharm Bull 2007;30:393-6
33. Otsuka Pharma Co. Ltd. Hirofumi T. Transpulmonary liposome for controlling drug arrival. EP2133097; 2009
34. Medgenesis Therapeutix, Inc. Redelmeier T, Luz M. Liposomal composition for convection-enhanced delivery to the central nervous centre. WO2010057317; 2010
35. Pacira Pharmaceuticals, Inc. Epidural administration of therapeutic compounds with sustained rate of release. EP2036542; 2009
36. Nanyang Technological University, Singapore Health Services Pte. Ltd. Venkatraman S, Natarajan JV, Wong T, Boey YCF. A liposomal formulation for ocular drug delivery. WO2012021107; 2012
37. Inst. Nagoya Ind. Science Res. Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye. EP2255788; 2010
38. Yamakazi N, Kojima S. Sugar-modified liposome and composition for drug delivery containing the liposome. WO2007018272; 2007
39. CeramOptec Industries, Inc. Farmer G, Scheglmann D, Albrecht V, Nifantiev NE. Photosensitizer formulations for topical applications. WO2007133514; 2007
40. Wayne State University, Scitech Development LLC. Parchment RE, Boinpally RR, Rose SE, et al. Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery. WO2007115134; 2007
41. Wang T, Deng Y, Geng Y, et al. Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim Biophys Acta 2006;1758:222-31
42. Yamamoto K, Mizutani Y, Nakanishi H, et al. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol 2008;33:565-71
43. Sun W, Zhang N, Li A, et al. Preparation and evaluation of N3-Otoluyl- loaded liposomes. Int J Pharm 2008;353:243-50
44. Watanabe M, Kawano K, Toma K, et al. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release 2008;127:231-8
45. Türker S, Erdogan S, Ozer YA, et al. Enhanced efficacy of diclofenac sodium-loaded lipogelosome formulation in intra-Articular treatment of rheumatoid arthritis. J Drug Target 2008;16:51-7
46. Celia C, Calvagno MG, Paolino D, et al. Improved in-vitro antitumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J Nanosci Nanotechnol 2008;8:2102-13
47. Fens MH, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer 2008;99:1256-64
48. Astellas Pharma, Inc. Takashi S. Liposome improving intracellular drug delivery. EP1795182; 2007
49. CeramOptec Industries, Inc. Albrecht V, Spaniol S, Scheglmann D. Pegylated compounds for age-related macular degeneration. WO2009067203; 2009
50. Fonseca C, Moreira JN, Ciudad CJ, et al. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm 2005;59:359-66
51. Terada T, Mizobata M, Kawakami S, et al. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 2007;119:262-70
52. Willis MC, Collins BD, Zhang T, et al. Liposome-Anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998;9:573-82
53. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008;1778:854-63
54. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010;141:183-92
55. Song CK, Jung SH, Kim DD, et al. Disaccharide-modified liposomes and their in vitro intracellular uptake. Int J Pharm 2009;380:161-9
56. Shmeeda H, Mak L, Tzemach D, et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006;5:818-24
57. Wu J, Lu Y, Lee A, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil. J Pharm Pharm Sci 2007;10:350-7
58. The Regents of the University of California. Zasadzinski JA, Wu G, Prevo B. Near infra-red pulsed laser triggered drug release from hollow nanoshell disrupted vesicles and vesosomes. WO2009097480; 2009
59. Dandamudi S, Campbell RB. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 2007;28:4673-83
60. Clares B, Biedma-Ortiz RA, Sáez-Fernández E, et al. Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. Eur J Pharm Biopharm 2013; doi: 10.1016/j.ejpb.2013.01.028
61. De Cuyper M, Soenen SJH, Coenegrachts K, Beek LT. Surface functionalization of magnetoliposomes in view of improving iron oxide-based magnetic resonance imaging contrast agents: Anchoring of gadolinium ions to a lipophilic chelate. Anal Biochem 2007;367:266-73
62. Gonzales M, Krishnan KM. Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mater 2005;293:265-70
63. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-305
64. Mok H, Zhang M. Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin Drug Deliv 2013;10:73-87
65. Zheng X, Goins BA, Cameron IL, et al. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother Pharmacol 2011;67:173-82
66. Yang FY, Wong TT, Teng MC, et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. J Control Release 2012;160:652-8
67. The Trustees of Columbia University in the City of New York. Kohane DS, Epstein-Barash H, Borden MA. Methods, devices, and systems for on-demand ultrasound-triggered drug delivery. WO2011075557; 2011
68. Speed CA. Therapeutic ultrasound in soft tissue lesions. Rheumatology 2001;40:1331-6
69. Schroeder A, Honen R, Turjeman K, et al. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 2009;137:63-8
70. Boston Scientific Corp. Mon J. Method of treating cancer comprising introduction of heat and delivery of liposome containing an active agent or thermo-Activated drug, gene or virus to tissue. WO2008039188; 2008
71. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 2001;53:307-19
72. Kim MJ, Lee HJ, Lee IA, et al. Preparation of pH-sensitive longcirculating and EGFR-targeted immunoliposomes. Arch Pharm Res 2008;31:539-46
73. Karanth H, Murthy RS. pH-sensitive liposomes: Principle and application in cancer therapy. J Pharm Pharmacol 2007;59:469-83
74. Northwestern University. Lee SM, Nguyen SB, ÓHalloran TV. Compositions and methods for polymer-caged liposomes. WO2008154500; 2008
75. Shum P, Kim JM, Thompson DH. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev 2001;53:273-84
76. Zhang ZY, Smith BD. High-generation polycationic dendrimers are unusually effective at disrupting anionic vesicles: Membrane bending model. Bioconjug Chem 2000;11:805-14
77. The General Hospital Corp. Zhu TF, Szostak J. Uniform-sized, multi-drug carrying and photosensitive liposomes for advanced drug delivery. WO2009091531; 2009
78. Davis SC, Szoka FC. Cholesterol phosphate derivatives: Synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. Bioconjug Chem 1998;9:783-92
79. Pak CC, Erukulla RK, Ahl PL, et al. Elastase-Activated liposomal delivery to nucleated cells. Biochim Biophys Acta 1999;1419:111-26
80. Villar AV, Goni FM, Alonso A. Diacylglycerol effects on phosphatydilinositol-specific phospholipase C activity and vesicle fusion. FEBS Lett 2001;494:117-20
81. Andresen TL, Davidsen J, Begtrup M, et al. Enzymatic release of anti-tumor ether lipids by specific phospholipase A2 activation of novel liposome-forming prodrugs. J Med Chem 2004;47:1694-703
82. Liplasome Pharma APS ApS. Vikbjerg AF, Petersen SA, Melander F, et al. Liposomes for drug delivery and methods for preparation thereof. WO2009141450; 2009
83. Academisch Medisch Centrum. Heger M. Drug delivery system for use in the treatment of vascular and vessel-related pathologies. WO2010084199; 2010
84. Pakunlu RI, Wang Y, Saad M, et al. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-62
85. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicinloaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci 2007;32:159-68
86. To BBB Holding B.V. Conjugates for targeted drug delivery across the blood-brain barrier. EP2308514; 2011
87. Universitá degli Studi Magna Graecia di Catanzaro. Fresta M, Russo D, Paolino D, Cosco D. TSH-conjugated nanocarrier for the treatment of thyroid cancer. WO2012073125; 2012
88. Japan Science & Tech Agency. Liposome allowing the discharge of substance entrapped therein from endosome. EP1832280; 2007
89. Lammers T, Kiessling F, Hennink WE, et al. Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Mol Pharm 2010;7:1899-912
90. Fang C, Zhang M. Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine. J Control Release 2010;146:2-5
91. Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2010;149:111-16
92. Kaimal V, Chu Z, Mahller YY, et al. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol 2011;13:886-97
93. Arias JL. Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging. Expert Opin Drug Deliv 2011;8:1589-608
94. Vaidya A, Sun Y, Feng Y, et al. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm Res 2008;25:2002-11
95. Comes Franchini M, Baldi G, Bonacchi D, et al. Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: A potential theranostic approach against cancer. Small 2010;6:366-70
96. von Maltzahn G, Park JH, Agrawal A, et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009;69:3892-900
97. Al-Jamal WT, Al-Jamal KT, Tian B, et al. Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. Mol Pharm 2009;6:520-30
98. Kyungpook National University Industry-Academic Cooperation Foundation, Industrial Technology Research Institute. Kim IS, Lee BH, Lu MJM, et al. Target-Aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof. WO2011081443; 2011
99. Luna Innovations, Inc. Zhou Z, Lenk RP, Kepley CL. Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque. WO2012135550; 2012
100. Kunzmann A, Andersson B, Thumherr T, et al. Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011;1810:361-73
101. Grainger DW. Nanotoxicity assessment: All small talk Adv Drug Deliv Rev 2009;61:419-21
102. Cattaneo AG, Gornati R, Sabbioni E, et al. Nanotechnology and human health: Risks and benefits. J Appl Toxicol 2010;30:730-44
103. Faunce TA. Toxicological and public good considerations for the regulation of nanomaterial-containing medical products. Expert Opin Drug Saf 2008;7:103-6
104. Wang B, Wang Z, Feng W, et al. New methods for nanotoxicology: Synchrotron radiation-based techniques. Anal Bioanal Chem 2010;398:667-76